Renal safety in patients treated with bisphosphonates for osteoporosis: A review

Journal of Bone and Mineral Research, 08/02/2013

Bisphosphonates are widely used for the treatment of osteoporosis and are generally well tolerated. However, the United States Food and Drug Administration safety reports have highlighted the issue of renal safety in bisphosphonate–treated patients. All bisphosphonates carry labeled “warnings” or a contraindication for use in patients with severe renal impairment (creatinine clearance <30 or <35?mL/min). All bisphosphonate therapies have “warnings” for use in patients with severe renal impairment. Clinical trial results have shown that even in elderly, frail osteoporotic patients with renal impairment, intravenous bisphosphonate therapy administration in accordance with the prescribing information did not result in long–term renal function decline. Physicians should follow guidelines for bisphosphonate therapies administration at all times.

Print Article Summary Cat 2 CME Report